Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E16.15 EPS (ttm)10.26 Insider Own0.10% Shs Outstand736.45M Perf Week-1.70%
Market Cap122.06B Forward P/E13.00 EPS next Y12.75 Insider Trans0.00% Shs Float735.42M Perf Month-4.75%
Income7.72B PEG2.52 EPS next Q3.00 Inst Own80.50% Short Float1.19% Perf Quarter14.17%
Sales22.99B P/S5.31 EPS this Y13.10% Inst Trans-1.79% Short Ratio2.22 Perf Half Y-4.33%
Book/sh40.59 P/B4.08 EPS next Y3.56% ROA10.10% Target Price186.07 Perf Year13.98%
Cash/sh51.71 P/C3.20 EPS next 5Y6.41% ROE25.90% 52W Range131.83 - 184.21 Perf YTD14.14%
Dividend4.60 P/FCF18.72 EPS past 5Y20.50% ROI13.00% 52W High-10.03% Beta1.25
Dividend %2.78% Quick Ratio3.90 Sales past 5Y8.10% Gross Margin81.90% 52W Low25.72% ATR3.21
Employees19200 Current Ratio4.10 Sales Q/Q7.70% Oper. Margin42.60% RSI (14)38.81 Volatility1.37% 1.53%
OptionableYes Debt/Eq1.16 EPS Q/Q10.50% Profit Margin33.60% Rel Volume0.80 Prev Close166.04
ShortableYes LT Debt/Eq1.01 EarningsFeb 02 AMC Payout38.70% Avg Volume3.96M Price165.74
Recom2.30 SMA20-5.85% SMA50-0.88% SMA2004.10% Volume3,172,190 Change-0.18%
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Mar-24-17 04:41PM  Why You're Smart to Buy Jazz Pharmaceuticals plc at Motley Fool
03:11PM  Google life sciences spinoff soaks up huge space (video) at bizjournals.com
01:44PM  Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?
11:27AM  Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
09:30AM  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General Electric and Carnival
05:24AM  Amgen Secures EU Approval for Anti-Inflammatory Drug at Investopedia
Mar-23-17 04:00PM  European Commission Approves AMGEVITA (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases PR Newswire
03:40PM  Stock Research Reports for Amgen, Berkshire & Walgreens
02:07PM  Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
10:57AM  Biotechs Back in the Doghouse After Failed Rally at Investopedia
09:00AM  How This Company Is Taking on Amgen at Motley Fool
Mar-22-17 03:21PM  Biotech giant plans $25M Tampa investment, 450 jobs at bizjournals.com
11:25AM  Health ETF Wobbles As Vote On Bill To Replace ObamaCare Nears; Gold Gains
09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
08:33AM  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
Mar-21-17 04:54PM  Sanofi and Regeneron Sue Amgen over Eczema Drug at Investopedia
02:45PM  Sanofi-Genzyme files preemptive legal strike to protect eczema drug at bizjournals.com
12:49PM  4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
12:33PM  Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims
11:00AM  ONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment
09:25AM  3 Biotech Stocks That Are Broker Favorites
Mar-20-17 08:08PM  Esperion Therapeutics Inc (ESPR): Get It While Its Cheap at Insider Monkey
05:02PM  Here's What Pushed Esperion Therapeutics Inc Stock Higher Today at Motley Fool
04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
01:18PM  Why Amgen's Success Was a Big Disappointment at Motley Fool
10:26AM  Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:40AM  There's a Middle Ground in Amgen's Drug-Price Battle
07:32AM  Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug at Forbes
04:55AM  Lowering LDL Levels with Repatha(R) (evolocumab) Did Not Adversely Affect Cognitive Function in Landmark Phase 3 Study PR Newswire
03:28AM  Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues PR Newswire
01:00AM  Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View
Mar-19-17 02:00PM  Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients PR Newswire
11:01AM  Is Trump Bad for Healthcare Stocks? These 4 Winners Don't Think So at Motley Fool
Mar-18-17 08:00AM  Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study PR Newswire
Mar-17-17 11:47PM  Amgens Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal -6.38%
11:43PM  [$$] Amgens Money-Back Guarantee at The Wall Street Journal
07:18PM  Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal
07:15PM  How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More
05:44PM  Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis
04:59PM  The Biggest Loser: Amgen Drops 6.4% at Barrons.com
04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
04:49PM  Amgen discounts cholesterol drug, but payers want more
04:30PM  Why Amgen, AmTrust Financial Services, and BRF Slumped Today at Motley Fool
04:28PM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
04:19PM  Markets Right Now: Early gain for stocks fades at close
04:07PM  New cholesterol-fighting drug slashes heart attack risk, but at a steep price; Amgen shares drop at CNBC
04:03PM  Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
02:56PM  Amgen, Esperion, AmTrust Financial and More: What is Going On With These Falling Stocks? at Insider Monkey
02:22PM  Nasdaq Hits Record High As Stocks Slowly Gain Steam
01:51PM  [$$] Amgen's Money-Back Guarantee at The Wall Street Journal
01:32PM  Stocks Turn Higher Even as Amgen Leads Another Health Care Selloff
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
01:03PM  CVS Health says Amgen data may increase eligible patients by millions
01:03PM  Amgen Blew ItFor Medicines Co., Esperion Too at Barrons.com
01:00PM  Amgen's Repatha Reduced Heart Attack, Stroke Risk at Investopedia
12:52PM  US STOCKS-Wall St flat as tech gains offset weakness in banks
12:46PM  Why Amgen's Getting Crushed at Barrons.com
12:40PM  Be Patient With Amgen After Its Major Breakdown
12:04PM  Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall at TheStreet
11:46AM  GLOBAL MARKETS-World stocks hover near peaks, dollar extends slide Reuters
11:38AM  US STOCKS-Wall St edges lower as financial stocks drag
11:22AM  Express Scripts says Amgen data opens door to patients
11:03AM  [video]AveXis, Esperion and Amgen Among Biotech Movers
10:38AM  Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate
10:37AM  This Key Measure Shows the S&P Could Be Headed for a 5% Pullback
10:09AM  US stocks mixed, still on pace for yet another winning week
10:04AM  US STOCKS-Wall St little changed as healthcare stocks weigh
09:33AM  5 Biotech Companies To Watch In 2017
09:00AM  Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues PR Newswire
09:00AM  Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study
08:48AM  What are Sanofi's (SNY) Strengths and Challenges in 2017?
Mar-16-17 05:52PM  Billion dollar boost for Amgen?
04:09PM  Markets Right Now: US indexes waver to mixed close
02:30PM  5 Biotech Companies Set for Major Breakouts In 2017
10:49AM  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
10:00AM  Does Amgen Offer a Great Value Buying Opportunity Right Now?
08:46AM  Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
08:05AM  Life-Saving Device Could Transform The Medical Market In 2017
Mar-15-17 07:01PM  Cramer: The Airlines and Health-Care Names Are Really Soaring
11:48AM  Jim Cramer: Amgen's Pipeline Positions It Well to Withstand a Rate Hike
09:55AM  Cramer's Stop Trading: Amgen's pipeline
Mar-14-17 04:15PM  Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology' PR Newswire
04:06PM  Amgen Could Boost Rivals On Positive Heart-Disease Study: Analyst
04:00PM  Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions PR Newswire
10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar-13-17 04:37PM  Amgen Tops Heart Study As Rivals Regeneron, Sanofi Chill In Court
09:24AM  Amgen's Repatha lowers need for cholesterol-lowering procedure
09:20AM  Amgen says its Repatha reduced need for high cholesterol therapy in late-stage clinical trial at MarketWatch
09:00AM  Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study PR Newswire
08:00AM  Early movers: MBLY, INTC, YHOO, BA, IT, NAV, DISH, F, AMGN & more at CNBC
01:00AM  Data on heart benefits of Amgen drug is key to unlocking sales
Mar-11-17 11:41AM  Which Biotech Is the Best Dividend Stock? at Motley Fool
Mar-10-17 07:27PM  World economy stronger than you think
06:53PM  Cramer's game plan: The world economy is stronger than yo...
06:15PM  Cramer's game plan: The world economy is stronger than you think this stock will prove it at CNBC
04:39PM  Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging'
01:12PM  AbbVie Stock Upgraded: What You Need to Know at Motley Fool
10:30AM  Major Biotechs See a Retreat in Short Interest
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM